Retatrutide, Eli Lilly's investigational triple hormone receptor agonist (GLP-1, GIP, and glucagon), posted strong Phase 3 results in two new trials: up to 20.8% weight loss in adults with type 2 diabetes and obesity (TRIUMPH-2), and up to 22.6% weight loss in adults with severe obesity and established cardiovascular disease (TRIUMPH-3). Lilly plans to file for FDA approval in Q1 2027; actual market availability would follow later (Eli Lilly, PR Newswire). It is not approved or available today.
What retatrutide is
Most currently available weight-loss injectables work on one or two hormone receptor pathways: semaglutide is a GLP-1 agonist; tirzepatide (Zepbound/Mounjaro) is a dual GLP-1/GIP agonist. Retatrutide goes a step further — it's a triple agonist, activating receptors for GLP-1, GIP, and glucagon simultaneously (Eli Lilly). Adding glucagon receptor activity is the mechanistic bet: glucagon increases energy expenditure and fat oxidation, which is part of why retatrutide has posted larger average weight-loss numbers in trials than dual or single-pathway drugs. It's dosed once weekly, with a gradual step-up schedule to manage GI side effects.
TRIUMPH-2 results
TRIUMPH-2 (NCT05929079) enrolled 1,152 adults with obesity or overweight and type 2 diabetes — a population that typically loses weight less easily on GLP-1 therapy than people without diabetes. Over 80 weeks:
| Arm | Weight change | A1C change |
|---|---|---|
| Retatrutide 4 mg | −12.7% (−29.8 lbs) | −1.4% |
| Retatrutide 9 mg | −19.1% (−45.4 lbs) | −1.6% |
| Retatrutide 12 mg | −20.8% (−49.6 lbs) | −1.5% |
| Placebo | −4.0% (−9.3 lbs) | −0.2% |
All three retatrutide doses beat placebo on both weight and glycemic control. The most common side effects were GI-related — diarrhea, nausea, constipation, decreased appetite — generally mild to moderate and improving over time. Discontinuation due to adverse events ranged from 3.8% to 11.6% across doses, versus 4.9% on placebo.
TRIUMPH-3 results
TRIUMPH-3 (NCT05882045) enrolled 1,949 adults with severe obesity (BMI ≥35 kg/m²) and established cardiovascular disease — precisely the population where safety data matters most. Over 80 weeks:
| Arm | Weight change |
|---|---|
| Retatrutide 9 mg | −21.6% (−52.7 lbs) |
| Retatrutide 12 mg | −22.6% (−55.8 lbs) |
| Placebo | −3.2% (−7.7 lbs) |
Cardiovascular safety signals were reassuring, not alarming: major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both arms, with a MACE-5 hazard ratio of 0.82 (95% CI 0.55–1.22) favoring retatrutide numerically, though the trial wasn't statistically powered to prove cardiovascular benefit. Highest-dose patients also saw meaningful drops in triglycerides (−37.0%), non-HDL cholesterol (−16.5%), systolic blood pressure (−9.3 mmHg), and hsCRP (−51.2%) — a broad favorable shift in cardiometabolic risk markers.
Why this matters for TRT patients
Testosterone replacement corrects hypogonadism — it does not reliably resolve obesity or metabolic syndrome, and a substantial share of men who present for TRT also carry excess visceral fat, insulin resistance, or diagnosed type 2 diabetes. Low testosterone and obesity often coexist and reinforce each other: excess adipose tissue increases aromatization of testosterone to estradiol and is associated with lower SHBG and lower total T, while low T itself is associated with increased fat mass.
That overlap means many TRT patients are also candidates for metabolic therapy, and the field is moving toward combination approaches — treating the hormonal deficiency and the metabolic burden as separate, co-managed problems rather than expecting testosterone alone to fix body composition. A triple agonist with this magnitude of weight loss, if approved, would be a meaningfully more powerful tool in that combination than currently available options.
Timeline and access
Retatrutide is not approved and cannot be legally sold or marketed for human use today — it remains an investigational molecule. Lilly says it is completing the Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application and plans to submit to the FDA in Q1 2027 (Eli Lilly). Standard FDA review timelines after a BLA submission typically run many months to over a year, which puts realistic patient availability closer to 2028 in the most optimistic case.
In the meantime, patients seeking metabolic support have access to compounded and brand-name semaglutide and tirzepatide through legitimate physician-prescribed pathways today — a meaningfully different regulatory and availability picture than an investigational molecule still a BLA submission away from FDA review.
Aurafil position
To be direct: we don't offer retatrutide. It isn't approved, and we don't prescribe unapproved investigational drugs. What we do is monitor trial data like TRIUMPH-2 and TRIUMPH-3 closely, because our patient population overlaps heavily with the population these trials studied — men managing both hormonal and metabolic health. When and if retatrutide clears FDA review, we'll evaluate it the same way we evaluate every therapy: against the evidence, not the headline.
This article is for educational purposes only. Nothing in it constitutes medical advice. Always consult your physician before starting, stopping, or changing any therapy.